TELA Bio Inc
TELA Bio Inc (TELA) develops and commercialises tissue‑guided repair implants for soft‑tissue reconstruction and hernia repair. The company’s products combine biologic and polymer components intended to support healing while reducing complications associated with traditional meshes. As a small‑cap medical devices firm with a market capitalisation around $60m, TELA is in a commercial and clinical growth phase: revenue trends, adoption by surgeons and reimbursement decisions will be key drivers. Investors should consider the typical biotech/medical‑device risks — limited liquidity, quarterly volatility, dependence on regulatory approvals and clinical outcomes, and competition from larger manufacturers. Financials may show uneven revenue while the company invests in sales and evidence generation. This summary is educational only and not investment advice; small‑cap healthcare stocks can be high risk and are suitable only for investors who understand potential for significant gains and losses.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying TELA Bio's stock with a target price of $14.2, showing strong growth potential.
Financial Health
TELA Bio Inc is performing well with strong revenue and cash flow, indicating solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring TELA
3D-Bioprinted Tissues
These cutting-edge companies are building the future of medicine by printing living human tissues layer by layer. Selected by expert analysts, this collection represents one of healthcare's most promising frontiers with potential to revolutionize transplantation and drug development.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Commercial Traction
Growing product sales and surgeon adoption could drive revenue, though early commercial profiles may be uneven and subject to reimbursement hurdles.
Clinical Evidence
Clinical studies and regulatory milestones can validate technology and expand use, but outcomes and approvals are uncertain and may affect valuation.
Competitive Market
There’s clear demand for improved soft‑tissue repair solutions globally, yet competition from established device makers and pricing pressures remain important risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
